Final height in short polytransfused thalassemia major patients treated with recombinant growth hormone

L. Cavallo, V. De Sanctis, M. Cisternino, M. Caruso Nicoletti, M. C. Galati, A. Acquafredda, C. Zecchino, M. Delvecchio

Research output: Contribution to journalArticlepeer-review

Abstract

We measured the final height (FH) of 25 short polytransfused thalassemia major (Th) patients (18 males) with a reduced GH reserve treated for 3.3±1.2 yr with recombinant GH (rhGH), 0.2 mg/kg/week sc. At baseline, all patients were clinically prepubertal; their chronological (CA) and bone ages (BA) were 13.6±2.0 and 11.4±1.6 yr, respectively. In 9 out of 18 males and 5 out of 7 females, the onset of puberty occurred spontaneously during the treatment. At the end of the rhGH administration, the height of the enrolled children was not significantly increased when calculated for CA (HxCA), while it was significantly decreased (p=0.004) when calculated for BA (HxBA); the BA increase (3.29±1.65 yr) was significantly higher (p

Original languageEnglish
Pages (from-to)363-366
Number of pages4
JournalJournal of Endocrinological Investigation
Volume28
Issue number4
Publication statusPublished - 2005

Keywords

  • Final height
  • Recombinant GH therapy
  • Thalassemia major

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Final height in short polytransfused thalassemia major patients treated with recombinant growth hormone'. Together they form a unique fingerprint.

Cite this